Author

Marianne Richter

Massachusetts General Hospital

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Molecular Biology· 3 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Organism:human· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Assay:proteomics· 2 Research Focus:differential expression· 1 Approach:statistical model· 1

Frequent Co-Authors

Benedikt R. Dürr· 3 shared Junbing ZhangiD· 3 shared Liron Bar‐PelediD· 3 shared Mariko TakahashiiD· 3 shared Nabeel M. BardeesyiD· 3 shared Stefan Andrew HarryiD· 3 shared Tzu-yi Yang· 3 shared Aaron N. HataiD· 2 shared

Activity by Year

2023-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMolecular Biology

Benedikt R. Dürr

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Antisense Oligonucleotides Targeting an LDLR Regulatory RNA Increase LDLR Expression and Reduce LDL-cholesterol in Vivo

Keerthana Gnanapradeepan, Salomé Manska, Brian Schwartz, Gabriel Golczer, Jiaqi Huang, Rachana S. Kelkar, Andrew M. Masteller, Shama Pilankar, Marianne Richter, Scott Waldron, Brynn N. Akerberg, Dale C. Guenther, Alla A. Sigova, David A. Bumcrot, Daniel F. Tardiff

This paper demonstrates that antisense oligonucleotides targeting LDLR regulatory RNAs increase LDLR expression and reduce LDL-cholesterol in a mouse model.

bioRxiv · Jun 4, 2026 · PreprintMolecular Biology

DrugMap: A quantitative pan-cancer analysis of cysteine ligandability

Mariko Takahashi, Harrison Byron Chong, Siwen Zhang, Tzu-yi Yang, Matthew J. Lazarov, Stefan Andrew Harry, Michelle Maynard, Brendan J. Hilbert, Ryan D. White, Heather E. Murrey, Chih‐Chiang Tsou, Kira Vordermark, Jonathan Assaad, Magdy Gohar, Benedikt R. Dürr, , Liron Bar‐Peled

DrugMap quantitatively analyzes cysteine ligandability across 416 cancer cell lines, revealing redox state, conformational changes, and mutations as drivers of variability, and identifies covalent inhibitors targeting NFκB1 and SOX10.

Cell · Apr 22, 2024Peer-reviewedSystems Biology

Identification of chemotherapy targets reveals a nucleus-to-mitochondria ROS sensing pathway

Junbing Zhang, Claire M. Simpson, Jacqueline Berner, Harrison Byron Chong, Jiafeng Fang, Zehra Ordulu, Tommy Weiss‐Sadan, Anthony P. Possemato, Stefan Andrew Harry, Mariko Takahashi, Tzu-yi Yang, Marianne Richter, Himani Patel, Abby E. Smith, Alexander Daniel Carlin, , Liron Bar‐Peled

The paper identifies a nucleus-to-mitochondria ROS sensing pathway involving CHK1 and SSBP1 that mediates resistance to platinum-based chemotherapies in ovarian cancers.

bioRxiv · Mar 11, 2023 · PreprintMolecular Biology

NRF2 activation induces NADH-reductive stress providing a metabolic vulnerability in lung cancer

Tommy Weiss‐Sadan, Maolin Ge, Makiko Hayashi, Magdy Gohar, Cong-Hui Yao, Adriaan de Groot, Stefan Andrew Harry, Alexander Daniel Carlin, Hannah Fischer, Lei Shi, Ting-Yu Wei, Charles H. Adelmann, Konstantin M. P. Wolf, Tristan Vornbäumen, Benedikt R. Dürr, , Liron Bar‐Peled

The paper shows NRF2 activation in KEAP1 wildtype lung cancers causes NADH-reductive stress, making them vulnerable to Complex I inhibition.

Cell Metabolism · Feb 24, 2023Peer-reviewedMolecular Biology